Table 4.

Comorbidities in all newly followed PLHIV and in those hospitalised for KD

Comorbidities	Total newly followed PLHIV n=1113	Newly followed PLHIV with KD n=66	p value*
Hepatitis co-infections, n, %	89 (8.0)	4 (6.1)	0.5708
Hypertension, n, %	53 (4.8)	5 (7.6)	0.3701
Diabetes mellitus, n, %	37 (3.3)	2 (3.0)	1.0000
Cardiovascular diseases†, n, %	28 (2.5)	5 (7.6)	0.0330
Dyslipidaemia, n, %	11 (1.0)	1 (1.5)	0.5007
Obesity, n, %	14 (1.3)	2 (3.0)	0.2243
Heart failure, n, %	5 (0.4)	1 (1.5)	0.2928

*Comparison between newly followed PLHIV hospitalised with KD and those without, Fisher’s exact test or χ².

†Cardiovascular diseases included coronary artery diseases, peripheral artery disease and stroke.

‡Hepatitis coinfections including hepatitis C and/or hepatitis B.

KD, kidney disease; PLHIV, people living with HIV.